Discover Great Companies Discover Great Clients
Companies Salaries Jobs
Jobs |
Jobs Companies Salary Majors

About the Company

南京凯地医疗技术有限公司是一家处于临床阶段的新药研发公司,公司致力于治疗恶性实体肿瘤的新型CAR-T细胞与基因治疗新药的研发。依托公司先进的合成生物学技术平台—KD-SmCAR™,凯地医疗已成功开发多条针对恶性实体肿瘤的CAR-T一类新药研发管线,含二代CAR-T、双靶向四代CAR-T及异体通用CAR-T,目前已申报CAR-T相关中美专利三十余件,近一年来获授权专利近10件,为国内外CAR-T*水平,其中核心管线KD-025专利均为中美首次授权。靶向NKG2DL适应症为肝癌及胶质瘤等的KD-025 CAR-T产品临床前研究成果先后在国际肿瘤免疫治疗权威杂志《Journal fImmunoTherapy of Cancer》和《Cancer Immunology Research》和美国肿瘤临床年会ASCO发表。目前正在多中心开展KD-025 CAR-T POC临床试验,已完成多例临床回输,无明显毒副反应,产品安全有效。同时,凯地正在以战略合作的方式加快推进KD-025 CAR-T国内外IND申报及多款新型 CAR-T IIT临床研究。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Recruitment Overview / Current Status (6 open positions)

Manage
Campus Recruitment & Advanced Degree Talent Demand
Master's 1
Note: How fast is hiring at 南京凯地医疗技术有限公司 growing? . A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 889.9288万(元)
Legal Representative: 代红久
Date Established:
Credit Code: 91320191MA22YM7TX0
Registered Address: 南京市江北新区华康路142号南京生物医药谷加速器三期A02栋4楼

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates

职业培训
客服
由百度提供